Abstracts tagged "Lung Disease"

Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Daphne Peelen¹, Ben Zwezerijnen², Esther Nossent¹, Lilian Meijboom¹, Otto Hoekstra³, Conny van der Laken⁴ and Alexandre Voskuyl⁴, ¹VUmc, Amsterdam, Netherlands, ²Nuclear Medicine, VUmc, Amsterdam, Netherlands, ³Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
Abstract Number: 400 • 2017 ACR/ARHP Annual Meeting
Combination of the Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation Models As a Model of Interstitial Lung Disease in Rheumatoid Arthritis
Katherine Janike¹, Jill Poole¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell W. Klassen⁴, Amy Nelson⁵, Kristi Warren⁶, Benjamin Swanson⁷ and Ted R. Mikuls⁸, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Int Med/Sec of Rheum/Immun, Univ of NE Medical Ctr, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, University of Nebrasa Medical Center, Omaha, NE, ⁶Department of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid Arthritis (RA) is characterized by extra-articular involvement including interstitial/inflammatory lung disease (ILD). Whereas the coexistence of RA and ILD is known, mechanisms…
Abstract Number: 568 • 2017 ACR/ARHP Annual Meeting
Complement Consumption As a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational Study
Alisson Pugliesi¹, RACHEL ZERBINI MARIANO², Raquel Baldini Campos³, Simone Appenzeller⁴, Manoel Bertolo⁵ and ZORAIDA SACHETTO¹, ¹INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ²Radiology and Diagnostic Imaging, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ³Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ⁴Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ⁵INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
Complement Consumption as a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational StudyBackground/Purpose: Primary Sjögren’s syndrome (pSS) may…
Abstract Number: 838 • 2017 ACR/ARHP Annual Meeting
Rates of New-Onset Pulmonary Disease Among Patients with Systemic Lupus Erythematosus in Sweden
Lindsy J. Forbess¹, Michael Weisman² and Julia F Simard³, ¹Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ³Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Our goal was to examine lung disease and types of pulmonary manifestations observed in patients with SLE. We studied population-based register data from Sweden…
Abstract Number: 1496 • 2016 ACR/ARHP Annual Meeting
Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease
Alex Zamora-Legoff¹, Megan Krause², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) carries a risk for serious infection due to lung disease, immunosuppressive therapy, and RA disease itself.…
Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Boyang Zheng¹, Normand Blais², Jean-Luc Senécal³, Gemma Perez⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Hematology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ³Université de Montréal, Montréal, QC, Canada, ⁴Laboratory of autoimmunity, Centre de Recherche du CHUM, Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…
Abstract Number: 1994 • 2016 ACR/ARHP Annual Meeting
Associations of Chronic Lung Comorbidity with Medications, Disease Activity, and All-Cause Mortality in Rheumatoid Arthritis
Bryant R. England^1,2, Harlan Sayles³, Kaleb Michaud^3,4, Liron Caplan⁵, Lisa A. Davis^6,7, Grant W. Cannon⁸, Brian Sauer⁹, E. Blair Solow¹⁰, Andreas Reimold¹¹, Gail S. Kerr¹², Pascale Schwab¹³, Joshua F. Baker¹⁴, Namrata Singh¹⁵ and Ted R. Mikuls¹⁶, ¹VA Nebraska-Western Iowa, Omaha, NE, ²Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS, ⁵Div of Rheumatology, Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁶Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁷Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁸Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ¹⁰Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹¹Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹²Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC, ¹³Div Arth & Rheum Dis, Portland VA and Oregon Health & Science University, Portland, OR, ¹⁴Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁵Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, ¹⁶Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While the impact of interstitial lung disease (ILD) on mortality in RA has been demonstrated, less is known about the influence of other lung…
Abstract Number: 2071 • 2016 ACR/ARHP Annual Meeting
Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen
Irina G. Luzina^1,2, Anne E. Wyman^1,2, Virginia Lockatell², Zahid Noor², Nevins W. Todd^1,2, Simeon E. Goldblum^1,2 and Sergei P. Atamas^1,2, ¹Baltimore VA Medical Center, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We and others have previously reported that pulmonary fibrosis in patients with scleroderma is accompanied by pulmonary accumulation of predominantly CD8+ T lymphocytes. Earlier…
Abstract Number: 2188 • 2016 ACR/ARHP Annual Meeting
Association Between Extent of Symptomatic Joint Involvement in Osteoarthritis and Comorbid Lung Disease in Patients Scheduled for Joint-Replacement Surgery
Anthony V. Perruccio^1,2,3, Rajiv Gandhi⁴, J. Denise Power^5,6 and Elizabeth M. Badley⁷, ¹The Arthritis Program, University Health Network, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Health Care & Outcomes Research, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Arthritis Program, Toronto, ON, Canada, ⁵Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶Dalla Lana School of Public Health, Toronto, ON, Canada, ⁷Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Comorbidity is highly prevalent in osteoarthritis (OA), although the origin of this is not well understood. The presence of multi-joint symptoms in OA, and…
Abstract Number: 2189 • 2016 ACR/ARHP Annual Meeting
The Association of Arthritis and Lung Diseases: A Population-Based Study
Elizabeth M. Badley^1,2, Marcia Maguire¹ and Anthony V. Perruccio^1,3, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: While rheumatoid arthritis is associated with a number of different lung conditions, the relationship with osteoarthritis, overwhelmingly the most frequent type of arthritis in…
Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Vincent Langlois¹, Kuberaka Mariampillai², Nicolas Champtiaux³, Marie-Laure Chabi⁴, Yurdagul Uzunhan⁵, Eric Hachulla⁶, Olivier Benveniste⁷ and Baptiste Hervier³, ¹Internal Medicine, University Hospital, Rouen, France, ²Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Radiology department, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Lille University Hospital, Lille, France, ⁷Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…
Abstract Number: 2429 • 2016 ACR/ARHP Annual Meeting
Mechanisms for the Development of Lung Fibrosis in Sting-Associated Vasculopathy with Onset in Infancy (SAVI)
Adriana Almeida de Jesus¹, Louise Malle¹, Dan Yang², Bernadette Marrero¹, Yin Liu³, Gina A. Montealegre Sanchez¹, Dawn C. Chapelle⁴, Hanna Kim⁴, Michelle O'Brien⁴, Gregor Dueckers⁵, Suzanne Ramsey⁶, Joseph R. Fontana⁷, Steven M. Holland⁸, Yan Huang¹, Suvimol Hill⁹, Laisa Santiago¹⁰, Benito Gonzalez¹¹, Paul Brogan¹², Juergen Brunner¹³, Ebun Omoyinmi¹⁴, Athimalaipet V Ramanan¹⁵, Amy Paller¹⁶, Olcay Y. Jones¹⁷, Seza Ozen¹⁸, Stephen Brooks⁴, Zuoming Deng⁴, Manfred Boehm¹⁹, Raphaela Goldbach-Mansky²⁰ and Helmut Wittkowski²¹, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ³Scientific Review Branch, NIAMS, NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, MD, ⁵Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Krefeld, Germany, ⁶Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁷Cardiovascular and Pulmonary Branch, NHLBI, NIH, Bethesda, MD, ⁸Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, MD, ⁹Radiology Department, Clinical Center, NIH, Bethesda, MD, ¹⁰Johns Hopkins All Children's Hospital Rheumatology, Saint Petersburg, FL, ¹¹Luis Calvo Mackenna Hospital, Santiago, Chile, ¹²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹³Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria, ¹⁴University College London Institute of Child Health, London, United Kingdom, ¹⁵University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ¹⁶Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA;, Chicago, IL, ¹⁷Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ¹⁹Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ²⁰Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²¹Department of Pediatric Rheumatology and Immunology, University Hospital of Muenster, Münster, Germany
Background/Purpose: STING-Associated Vasculopathy with Onset in Infancy (SAVI) is a monogenic autoinflammatory interferonopathy caused by gain-of-function mutations in TMEM173/STING, a nucleic acid sensor adaptor linked…
Abstract Number: 2583 • 2016 ACR/ARHP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Carlos Fernández-Díaz¹, Javier Loricera¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia E. Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez-Muguruza⁴, Bryan Josue Robles Flores⁹, Blanca Hernández-Cruz¹⁰, Ana Urruticoechea¹¹, O. Maiz Alonso¹², Desiree Palma¹³, Luis Arboleya¹⁴, Gema Bonilla¹⁵, Íñigo Hernández-Rodríguez¹⁶, Concepción Delgado¹⁷, Rosa Expósito Molinero¹⁸, Ana Ruibal Escribano¹⁹, Juan Blanco Madrigal²⁰, José Antonio Bernal²¹, Manuel Rodríguez-Gómez²², Paloma Vela Casasempere²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Francisco Ortiz Sanjuan²⁶, Javier Narváez²⁷, Manuel Jose Moreno²⁸, Mireia Lopez-corbeto²⁹, Natalia Mena-Vazquez³⁰, Lucia C. Domínguez-Casas¹, Clara Aguilera-Cros³¹, Victor Mora-Cuesta³², Natalia Palmou-Fontana¹, Miguel Angel Gonzalez-Gay³³, José Luis Hernandez³⁴ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁵Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de Leon, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Can Misses, Ibiza, Spain, ¹²Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹³Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁴Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁵Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ¹⁶Rheumatology, CHUVI Vigo, Vigo, Spain, ¹⁷Rheumatology, Hospital Clinico Universitario Lozano Blesa, zaragoza, Spain, ¹⁸Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ¹⁹Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²⁰Rheumatology, Hospital de Basurto, BIlbao, Spain, ²¹Sección de Reumatología, Hospital General de Alicante, Alicante, Spain, ²²Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²³Rheumatology, Hospital General de Alicante, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology, Hospital La Fe, Valencia, Spain, ²⁷Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ²⁸Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁹Hospital Universitario Vall d'Hebron, Barcelona, Spain, ³⁰Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³³Department of RheumaRheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). A potential association of anti-TNFα drugs and conventional disease-modifying anti-rheumatic drugs…
Abstract Number: 2677 • 2016 ACR/ARHP Annual Meeting
Clinical Features of Primary Sjogren’s Syndrome Associated Lung Involvement with Extro-Glandular Manifestations at Onset
Hui Gao¹, Xuewu Zhang^1,2 and Zhan-Guo Li^1,3, ¹Peking University International Hospital, Beijing, China, ²Rheumatology, Peking University People's Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: To investigate the common initial clinical presentations of primary Sjogren’s syndrome with pulmonary complications, and to explore the differences between patients with extro-glandular manifestations…
Abstract Number: 2894 • 2016 ACR/ARHP Annual Meeting
Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease
Ahmet Mesut Onat¹, Orhan Zengin¹, Savas Aksoy¹, Mustafa Erkut Onder¹, Koray Gorkem Sacıntı² and Bunyamin Kisacik¹, ¹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²Gaziantep University, School of Medicine, Gaziantep, Turkey
Background/Purpose: Systemic sclerosis (SSc) is a progressive fibrotic and autoimmune disease, which results to severe systemic complications. Rituximab (Rtx), an anti CD-20 antibody, has recently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].